Hematopoiesis News Volume 6.48 | Dec 8 2015

SF3B1 Mutant MDS-Initiating Cells May Arise from the Hematopoietic Stem Cell Compartment
Scientists demonstrated that SF3B1 mutation(s) in a cohort of myelodysplastic syndrome (MDS) patients with ring sideroblasts can arise from CD34⁺CD38⁻CD45RA⁻CD90⁺CD49f⁺ hematopoietic stem cells and is an initiating event in disease pathogenesis. [Nat Commun] Full Article

Targeting Acute Myeloid Leukemia with a Small Molecule Inhibitor of the Myb/p300 Interaction
Investigators demonstrated that celastrol suppresses the proliferative potential of acute myeloid leukemia cells while not affecting normal hematopoietic progenitor cells. [Blood] Abstract

MTSS1 Is a Critical Epigenetically Regulated Tumor Suppressor in CML
Scientists identified metastasis suppressor 1 (Mtss1/MIM) to be downregulated in hematopoietic stem and progenitor cells from leukemic transgenic SCLtTA/Bcr-Abl mice and in patients with chronic myeloid leukemia (CML) at diagnosis, and Mtss1 was restored when patients achieved complete remission. [Leukemia] Abstract

Identification of CD25 as STAT5-Dependent Growth-Regulator of Leukemic Stem Cells in Ph⁺ CML
In contrast to normal hematopoietic stem cells, CD34⁺/CD38^– chronic myeloid leukemia (CML) leukemic stem cells expressed the interleukin-2 receptor alpha chain, IL-2RA (CD25). STAT5 was found to induce expression of CD25 in Lin^–/Sca^–1⁺/Kit⁺ stem cells in C57Bl/6 mice [Clin Cancer Res] Abstract

The Ribosome Biogenesis Protein Nol9 Is Essential for Definitive Hematopoiesis and Pancreas Morphogenesis in Zebrafish
Researchers describe a zebrafish mutant with a loss-of-function mutation in nol9. The nol9^{sa1022/sa1022} larvae displayed hypoplastic pancreas, liver and intestine and had decreased numbers of hematopoietic stem and progenitor cells. [PLoS Genet] Full Article

CLINICAL RESEARCH

Rapid Expansion of Pre-Existing Non-Leukemic Hematopoietic Clones Frequently Follows Induction Therapy for De Novo AML
Investigators report that five of 15 patients with genetic clearance of their founding acute myelogenous leukemia (AML) clone after induction chemotherapy had a concomitant expansion of a hematopoietic population unrelated to the initial AML. [Blood] Abstract

Does Ex Vivo CD34⁺ Positive Selection Influence Outcome after Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients?
Scientists demonstrated that CD34⁺ does not add benefit to the outcome of systemic sclerosis patient treated with autologous hematopoietic stem cell transplantation. [Bone Marrow Transplant] Abstract

Outcome of Second Allogeneic HCT following Relapse of Myeloid Malignancies Post Allogeneic HCT, a Retrospective Cohort on Behalf of the GETH
Researchers present a retrospective cohort of 116 patients diagnosed with acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative disorders who consecutively underwent a second allogeneic stem cell transplantation (HCT) for disease relapse. [Biol Blood Marrow Transplant] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

Amgen Presents Data from Three Trials Evaluating BLINCYTO^® (Blinatumomab) In Acute Lymphoblastic Leukemia
Amgen announced that new data from three Phase II trials support the efficacy and safety of BLINCYTO^® in adults with acute lymphoblastic leukemia. [Press release from Amgen, Inc. discussing research presented at the 57^th American Society of Hematology (ASH) Annual Meeting, Orlando] Press Release

From our sponsor: Learn about detecting cancer stem cells with ALDEFLUOR™. Watch the webinar.

Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of BENDEKA™ (Bendamustine Hydrochloride) Injection
Teva Pharmaceutical Industries Ltd. and Eagle Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved BENDEKA™ injection. BENDEKA is approved for the treatment of patients with chronic lymphocytic leukemia and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. [Teva Pharmaceutical Industries Ltd.] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the hematopoiesis community.

Postdoctoral Fellow – Leukemia and Lymphoma (Emory University)

Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

Team Leader/Professor/Associate Professor – Regenerative Medicine (Ji Nan University)

Postdoctoral Researcher – Cardiovascular/Hematopoietic Development (Kumamoto University)

Postdoctoral Fellow – Leukemia Research (City of Hope)

Postdoctoral Position – Stem Cells and Leukemia (Florida State University)

Assistant or Associate Professor – Cell and Regenerative Biology (University of Wisconsin, Madison)

Postdoctoral Research Fellow – Medicinal Chemistry for Cancer Drug Discovery (University of Michigan)

Postdoctoral Fellow – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.